loading
Precedente Chiudi:
$15.60
Aprire:
$15.21
Volume 24 ore:
23.34M
Relative Volume:
1.07
Capitalizzazione di mercato:
$3.31B
Reddito:
$1.78B
Utile/perdita netta:
$164.40M
Rapporto P/E:
21.04
EPS:
0.69
Flusso di cassa netto:
$236.51M
1 W Prestazione:
-7.10%
1M Prestazione:
-51.08%
6M Prestazione:
-67.01%
1 anno Prestazione:
-64.88%
Intervallo 1D:
Value
$14.48
$15.29
Intervallo di 1 settimana:
Value
$13.74
$16.46
Portata 52W:
Value
$13.74
$70.43

Hims Hers Health Inc Stock (HIMS) Company Profile

Name
Nome
Hims Hers Health Inc
Name
Telefono
415-851-0195
Name
Indirizzo
2269 CHESTNUT ST, SAN FRANCISCO
Name
Dipendente
2,442
Name
Cinguettio
Name
Prossima data di guadagno
2025-02-24
Name
Ultimi documenti SEC
Name
HIMS's Discussions on Twitter

Compare HIMS vs TAK, ZTS, HLN, TEVA, UTHR

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - Specialty & Generic icon
HIMS
Hims Hers Health Inc
14.52 3.56B 1.78B 164.40M 236.51M 0.69
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
18.75 58.54B 29.85B 776.90M 4.35B 0.2408
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
131.10 54.78B 9.47B 2.67B 2.28B 6.0218
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
11.07 47.92B 14.26B 1.98B 2.47B 0.4327
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
33.86 39.33B 17.41B 1.43B 1.00B 1.2182
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
503.90 21.68B 3.13B 1.27B 1.12B 26.39

Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2026-01-12 Iniziato Evercore ISI In-line
2025-12-09 Iniziato Barclays Overweight
2025-10-21 Iniziato KeyBanc Capital Markets Sector Weight
2025-06-23 Downgrade Needham Buy → Hold
2025-06-04 Reiterato Needham Buy
2025-04-29 Downgrade TD Cowen Buy → Hold
2025-02-18 Downgrade Morgan Stanley Overweight → Equal-Weight
2025-01-10 Downgrade Citigroup Neutral → Sell
2025-01-07 Iniziato BTIG Research Buy
2024-12-17 Iniziato Morgan Stanley Overweight
2024-11-14 Downgrade BofA Securities Buy → Underperform
2024-08-22 Iniziato Needham Buy
2024-08-09 Downgrade Imperial Capital Outperform → In-line
2024-05-22 Downgrade Citigroup Buy → Neutral
2024-04-16 Downgrade Jefferies Buy → Hold
2024-04-10 Iniziato Canaccord Genuity Buy
2024-02-28 Aggiornamento Imperial Capital In-line → Outperform
2024-02-26 Iniziato Leerink Partners Market Perform
2023-12-07 Iniziato Imperial Capital In-line
2023-07-28 Iniziato TD Cowen Outperform
2023-04-11 Iniziato Robert W. Baird Neutral
2023-02-09 Aggiornamento Jefferies Hold → Buy
2022-11-08 Aggiornamento BofA Securities Neutral → Buy
2022-11-08 Aggiornamento SVB Leerink Mkt Perform → Outperform
2022-10-17 Downgrade Piper Sandler Overweight → Neutral
2022-09-07 Iniziato Truist Hold
2022-07-15 Iniziato SVB Leerink Underperform
2022-04-14 Iniziato Guggenheim Buy
2022-04-01 Ripresa Credit Suisse Outperform
2022-03-10 Iniziato Deutsche Bank Hold
2021-12-02 Iniziato Jefferies Hold
2021-11-11 Aggiornamento Piper Sandler Neutral → Overweight
2021-07-06 Iniziato BofA Securities Neutral
2021-05-20 Aggiornamento Credit Suisse Neutral → Outperform
2021-04-21 Iniziato Truist Hold
2021-03-09 Iniziato Credit Suisse Neutral
2021-03-02 Aggiornamento Citigroup Neutral → Buy
2021-02-17 Iniziato Citigroup Neutral
2021-02-12 Iniziato Piper Sandler Neutral
2021-02-08 Iniziato Tigress Financial Buy
Mostra tutto

Hims Hers Health Inc Borsa (HIMS) Ultime notizie

pulisher
Feb 26, 2026

10 Health Care Stocks Whale Activity In Today's Session - Benzinga

Feb 26, 2026
pulisher
Feb 26, 2026

Hims & Hers at the Crossroads: Navigating the ‘Regulatory Winter’ of 2026 - FinancialContent

Feb 26, 2026
pulisher
Feb 26, 2026

The Complicated Legal Battle Between Novo Nordisk and Hims & Hers - The Fashion Law

Feb 26, 2026
pulisher
Feb 26, 2026

Hims & Hers stock steadies in premarket as Citi cuts target, SEC probe keeps GLP-1 risks in play - TechStock²

Feb 26, 2026
pulisher
Feb 26, 2026

Hims & Hers: The Telehealth Growth Story Younger Investors Can't Afford to Ignore - Yahoo Finance

Feb 26, 2026
pulisher
Feb 26, 2026

Hims & Hers: The Telehealth Growth Story Younger Investors Can't Afford to Ignore - The Motley Fool

Feb 26, 2026
pulisher
Feb 25, 2026

The Law Offices of Frank R. Cruz Announces Investigation of Hims & Hers Health, Inc. (HIMS) on Behalf of Investors - The AI Journal

Feb 25, 2026
pulisher
Feb 25, 2026

Hims & Hers Posts Robust Growth Boosted by New Acquisition - timothysykes.com

Feb 25, 2026
pulisher
Feb 25, 2026

HIMS vs. AMWL: Which Telehealth Stock Is the Better Investment Now? - The Globe and Mail

Feb 25, 2026
pulisher
Feb 25, 2026

Barclays Lowers Price Target for HIMS to $25, Maintains Overweig - GuruFocus

Feb 25, 2026
pulisher
Feb 25, 2026

Morgan Stanley Lowers Price Target for HIMS to $21 | HIMS Stock News - GuruFocus

Feb 25, 2026
pulisher
Feb 25, 2026

Hims & Hers Health: The GLP-1 Party Is Over (NYSE:HIMS) - Seeking Alpha

Feb 25, 2026
pulisher
Feb 25, 2026

Hims & Hers Health, Inc. (NYSE:HIMS) Q4 2025 Earnings Call Transcript - Insider Monkey

Feb 25, 2026
pulisher
Feb 25, 2026

Discipline and Rules-Based Execution in HIMS Response - Stock Traders Daily

Feb 25, 2026
pulisher
Feb 25, 2026

Hims And Hers Balances GLP 1 Scrutiny With Eucalyptus Expansion Plans - Yahoo Finance

Feb 25, 2026
pulisher
Feb 25, 2026

Regulatory Scrutiny of Compounded Drugs Puts Hims & Hers’ Growth, Partnerships, and Liability Risk in the Spotlight - TipRanks

Feb 25, 2026
pulisher
Feb 24, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Hims & Hers Health, Inc. (HIMS) And Encourages Shareholders to Connect - ACCESS Newswire

Feb 24, 2026
pulisher
Feb 24, 2026

Hims & Hers Earnings Call Signals Growth Amid Risks - TipRanks

Feb 24, 2026
pulisher
Feb 24, 2026

These Stocks Are Today’s Movers: AMD, Hims & Hers, Keysight, IBM, Kratos, Vir Biotechnology, Whirlpool, and More - Barron's

Feb 24, 2026
pulisher
Feb 24, 2026

Earnings live: Home Depot stock climbs after earnings beat, Hims & Hers slides, Constellation Energy rises - Yahoo Finance

Feb 24, 2026
pulisher
Feb 24, 2026

HIMS Analyst Rating Update: Leerink Partners Lowers Price Target - GuruFocus

Feb 24, 2026
pulisher
Feb 24, 2026

Hims & Hers Health: Don't Get Lost In The Weeds (NYSE:HIMS) - Seeking Alpha

Feb 24, 2026
pulisher
Feb 24, 2026

HIMS: Analyst TD Cowen Lowers Price Target to $17.00 | HIMS Stoc - GuruFocus

Feb 24, 2026
pulisher
Feb 24, 2026

Hims & Hers Health: Great Vision, Now On Sale -- Here's Why I'm Upgrading (NYSE:HIMS) - Seeking Alpha

Feb 24, 2026
pulisher
Feb 24, 2026

HIMS Analyst Rating Update: Citigroup Lowers Price Target | HIMS Stock News - GuruFocus

Feb 24, 2026
pulisher
Feb 24, 2026

Hims & Hers Stock Faces Heavy Sell-Off Amid SEC Probe Into GLP-1 Disclosures - GuruFocus

Feb 24, 2026
pulisher
Feb 24, 2026

HIMS Stock Plummets After Wall Street Downgrade, Price Target Cuts Following 'Disappointing' Q4 Report - Stocktwits

Feb 24, 2026
pulisher
Feb 24, 2026

HIMS: BTIG Downgrades Hims & Hers Health to Neutral | HIMS Stock News - GuruFocus

Feb 24, 2026
pulisher
Feb 24, 2026

Jefferies holds Hims and Hers stock rating at Hold on guidance concerns - Investing.com Nigeria

Feb 24, 2026
pulisher
Feb 24, 2026

Hims & Hers Health Analysts Cut Their Forecasts After Q4 Results - Benzinga

Feb 24, 2026
pulisher
Feb 24, 2026

Hims & Hers Stock Slips Despite Q4 Earnings Beat, Margins Contract - Yahoo Finance

Feb 24, 2026
pulisher
Feb 24, 2026

AMD, Hims & Hers, Keysight, Novo Nordisk, IBM, Kratos, Vir, and More Movers - Barron's

Feb 24, 2026
pulisher
Feb 24, 2026

Truist Securities Reiterates Hold Rating on HIMS, Lowers Price T - GuruFocus

Feb 24, 2026
pulisher
Feb 24, 2026

Truist cuts Hims and Hers stock price target on quarterly ramp concerns - Investing.com India

Feb 24, 2026
pulisher
Feb 24, 2026

Evercore ISI Group Lowers Price Target for Hims & Hers Health (H - GuruFocus

Feb 24, 2026
pulisher
Feb 24, 2026

Hims & Hers Health (HIMS) Stock Plunges 7-9% to Near $14 After Soft Q1 2026 Guidance Despite Q4 Beat - International Business Times Australia

Feb 24, 2026
pulisher
Feb 24, 2026

Hims & Hers Faces Investor Scrutiny Amid Regulatory and Growth Challenges - AD HOC NEWS

Feb 24, 2026
pulisher
Feb 24, 2026

Hims & Hers Health (NYSE:HIMS) Trading Down 6.3% After Analyst Downgrade - MarketBeat

Feb 24, 2026
pulisher
Feb 24, 2026

Biggest stock movers Tuesday: HIMS, VIR, CLVT, and more - Seeking Alpha

Feb 24, 2026
pulisher
Feb 24, 2026

Hims & Hers Stock Drops. Why Earnings Are Underwhelming Investors. - Barron's

Feb 24, 2026
pulisher
Feb 24, 2026

AMD, Hims & Hers, Home Depot, Kratos, Novo Nordisk, IBM, Keysight, Vir Biotechnology, and More Movers - Barron's

Feb 24, 2026
pulisher
Feb 24, 2026

Meta, AMD announce chip partnership, Novo Nordisk cuts US GLP-1 prices - Yahoo Finance

Feb 24, 2026
pulisher
Feb 24, 2026

KeyBanc maintains Hims and Hers stock rating on revenue outlook - Investing.com

Feb 24, 2026
pulisher
Feb 24, 2026

Hims & Hers Health Stock (HIMS) Opinions on Q4 Earnings Release - Quiver Quantitative

Feb 24, 2026
pulisher
Feb 24, 2026

Novo Nordisk: Investors Focusing On CagriSema Results Are Missing The Big Picture (NVO) - Seeking Alpha

Feb 24, 2026
pulisher
Feb 24, 2026

Hims & Hers Health After The GLP-1 Collapse - Seeking Alpha

Feb 24, 2026
pulisher
Feb 24, 2026

Hims & Hers Stock StumblesCautions About Pressure Due To Super Bowl Ad, Change In Shipping Cadences - Benzinga

Feb 24, 2026
pulisher
Feb 24, 2026

Hims & Hers Health, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance

Feb 24, 2026
pulisher
Feb 24, 2026

Hims & Hers Health (NYSE:HIMS) Cut to "Neutral" at BTIG Research - MarketBeat

Feb 24, 2026
pulisher
Feb 24, 2026

Earnings live: Hims & Hers stock slides, Domino's rises as investors await crucial update from Nvidia - Yahoo Finance

Feb 24, 2026
pulisher
Feb 24, 2026

AMD, Home Depot, Novo Nordisk, Hims & Hers, Keysight, Vir Biotechnology, and More Movers - Barron's

Feb 24, 2026

Hims Hers Health Inc Azioni (HIMS) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
drug_manufacturers_specialty_generic RDY
$14.38
price down icon 1.37%
drug_manufacturers_specialty_generic RGC
$26.23
price down icon 0.23%
$26.40
price up icon 0.80%
$132.25
price up icon 1.23%
$14.93
price down icon 2.10%
$503.90
price up icon 0.06%
Capitalizzazione:     |  Volume (24 ore):